

[10.1071/SH22203](https://doi.org/10.1071/SH22203)

*Sexual Health*

### Supplementary Material

#### **Evaluation of between-assay consistency among laboratory testing methods for neurosyphilis: a systematic review**

*Xu Zhang<sup>A</sup>, Fang-Zhi Du<sup>A</sup>, Qian-Qiu Wang<sup>A,\*</sup>, and Rui-Li Zhang<sup>B,\*</sup>*

<sup>A</sup>Institute of Dermatology, Chinese Academy of Medical Science & Peking Union Medical College, National Center for STD Control, China Centers for Disease Control and Prevention, Nanjing 210042, China.

<sup>B</sup>Department of Dermatology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China.

\*Correspondence to: Qian-Qiu Wang Institute of Dermatology, Chinese Academy of Medical Science & Peking Union Medical College, National Center for STD Control, China Centers for Disease Control and Prevention, Nanjing 210042, China Email: wangqianqun@126.com Rui-Li Zhang Department of Dermatology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China Email: reallyvictor@126.com

**Supplementary Table S1.** Results of consistency analysis between CSF-VDRL and CSF-RPR among collected studies\*

(A) CSF-VDRL vs. CSF-RPR

Study	RPR+ and VDRL+	RPR+ and VDRL-	RPR- and VDRL+	RPR- and VDRL-	McNemar's X <sup>2</sup>	P	k
Versiani <i>et al.</i> <sup>6</sup>	21	0	0	99	—	—	1
Zhu <i>et al.</i> <sup>7</sup>	217	0	44	871	42.023	< 0.001	0.884
Castro <i>et al.</i> <sup>8</sup>	16	3	1	4	0.250	0.617	0.560
Marra <i>et al.</i> <sup>9</sup>	29	0	16	104	14.000	< 0.001	0.717
Lin <i>et al.</i> <sup>10</sup>	57	2	4	293	0.167	0.683	0.940

\*CSF, cerebrospinal fluid; VDRL, venereal disease research laboratory test; RPR, rapid plasma reagin;

(B) CSF-VDRL vs. CSF-TRUST

Study	TRUST+ and VDRL+	TRUST+ and VDRL-	TRUST- and VDRL+	TRUST- and VDRL-	McNemar's X <sup>2</sup>	P	k
Zhu <i>et al.</i> <sup>7</sup>	220	0	41	871	39.024	$4.185 \times 10^{-10}$	0.892

\*CSF, cerebrospinal fluid; VDRL, venereal disease research laboratory test; RPR, rapid plasma reagin; TRUST, toluidine red unheated serum test.

**Supplementary Table S2(A).** Performance of CSF-RPR and CSF-VDRL tests distinguished as symptomatic or asymptomatic

Study	Symptomatic NS				Asymptomatic NS			
	Sensitivity by VDRL	Specificity by VDRL	Sensitivity by RPR	Specificity by RPR	Sensitivity by VDRL	Specificity by VDRL	Sensitivity by RPR	Specificity by RPR
Zhu <i>et al.</i> <sup>7</sup>	85.7	86.7	81.8	90.2	69.6	79.4	60.7	82.6
Marra <i>et al.</i> <sup>9</sup>	66.7	80.2	51.5	89.7	71.8	98.3	56.4	100

or

**Supplementary Table S2(B).** Performance of CSF-TRUST and CSF-VDRL tests distinguished as symptomatic or asymptomatic

	Symptomatic NS				Asymptomatic NS			
	Sensitivity by VDRL	Specificity by VDRL	Sensitivity by TRUST	Specificity by TRUST	Sensitivity by VDRL	Specificity by VDRL	Sensitivity by TRUST	Specificity by TRUST
Zhu <i>et al.</i> <sup>7</sup>	85.7	86.7	82.5	90.1	69.6	79.4	58.9	82.1

**Supplementary Table S3.** Performance of CSF-RPR and CSF-VDRL tests in studies that included or excluded HIV+ participants

Study	Sensitivity by VDRL	Specificity by VDRL	Sensitivity by RPR	Specificity by RPR
Studies including HIV+ participants				
Castro <i>et al.</i> <sup>8</sup>	99	70.8	99.3	75
Marra <i>et al.</i> <sup>9</sup>	71.8/66.7	98.3/80.2	56.4/51.5	100/89.7
Study excluding HIV+ participants				
Zhu <i>et al.</i> <sup>7</sup>	81.4	90.3	76.2	93.4